Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts

Non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations initially respond well to the EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. However, clinical efficacy is limited by the development of resistance. In most cases, this resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Peng, Han, Da-xiong, Ruan, Run-sheng, Zheng, Li-Mou, Chou, Shiu-Huey, Tzeng, Chi-Meng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094958/
https://www.ncbi.nlm.nih.gov/pubmed/26848869
http://dx.doi.org/10.18632/oncotarget.7140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094958/
https://www.ncbi.nlm.nih.gov/pubmed/26848869
http://dx.doi.org/10.18632/oncotarget.7140

Ejemplares similares